

Milton Packer
In the REVIVE trial the inotropic agent levosimendan has improved short-term outcome in acutely decompensated heart failure. Milton Packer from the University of Texas.
[audio:https://www.audiomedica.com/podcasting/aha2005/Milton_Packer.mp3]